{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T06:39:51Z","timestamp":1791614391516,"version":"4.3.4"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"vor","delay-in-days":16,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003246","name":"Nederlandse Organisatie voor Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["projectnummer NWA.1389.20.244"],"award-info":[{"award-number":["projectnummer NWA.1389.20.244"]}],"id":[{"id":"10.13039\/501100003246","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Research on the development of prognostic biomarker-based models for genetic neurodegenerative diseases lacking disease-modifying treatments is advancing rapidly. Currently, prognostic models are being developed to predict individual disease onset and progression rates for Huntington\u2019s disease, spinocerebellar ataxia type 1, and spinocerebellar ataxia type 3. These models have potential applications in research, such as evaluating onset-delaying treatments and their timing, and in clinical practice, where they may offer personal utility to mutation carriers. However, the perspectives of healthcare professionals in genetic counselling have not yet been adequately explored.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this qualitative interview study, we interviewed 18 Dutch healthcare professionals in genetic counselling, representing the majority of the Dutch counselling practice for these conditions, to explore their views on using onset and progression predictions in clinical practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Healthcare professionals highlighted potential benefits, such as reducing uncertainty and supporting informed life and family planning, which are among the pivotal reasons for mutation carriers to opt for predictive genetic testing. They also noted possible drawbacks, including psychological distress for mutation carriers, discussed challenges in defining clinical disease onset, and some questioned the degree of personal utility of these predictions. Finally, healthcare professionals emphasised several key conditions for implementing such prognostic models, including sufficient predictive accuracy, a narrower and more precise age range, and the need for additional counselling.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study provides insights in the perspectives, views, and concerns of the majority of healthcare professionals in the Dutch counselling practice regarding the use of onset and progression predictions. Healthcare professionals identified several potential benefits and drawbacks of onset and progression predictions and discussed the conditions necessary for their implementation. During model development and before clinical implementation, clarity is needed on how disease onset is defined in the model and what constitutes sufficient model performance. Furthermore, aligning the model with its intended goals, such as providing personal utility, and assessing the feasibility of achieving meaningful predictions are important steps.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-026-04396-1","type":"journal-article","created":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T09:24:49Z","timestamp":1778664289000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Developing prognostic models that predict onset and progression rates in genetic neurodegenerative diseases: perspectives of healthcare professionals in genetic counselling"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4799-8587","authenticated-orcid":false,"given":"Max J.","family":"Rensink","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9575-1354","authenticated-orcid":false,"given":"L. L. E.","family":"Bolt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4560-1710","authenticated-orcid":false,"given":"A.","family":"Tibben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0732-4406","authenticated-orcid":false,"given":"M.","family":"Oosterloo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4412-1616","authenticated-orcid":false,"given":"B. P. C. van de","family":"Warrenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4283-9659","authenticated-orcid":false,"given":"M. H. N.","family":"Schermer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,13]]},"reference":[{"key":"4396_CR1","unstructured":"Caron NS, Wright GEB, Hayden MR. Huntington disease. GeneReviews\u00ae[Internet]. 1998. Last update: 2026"},{"key":"4396_CR2","unstructured":"Bhandari JTP, Samanta D. Spinocerebellar Ataxia. StatPearls [Internet]. 2023."},{"issue":"8","key":"4396_CR3","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/gm80","volume":"1","author":"JF Gusella","year":"2009","unstructured":"Gusella JF, MacDonald ME. Huntington\u2019s disease: the case for genetic modifiers. Genome Med. 2009;1(8):80.","journal-title":"Genome Med"},{"issue":"2","key":"4396_CR4","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1002\/ajmg.b.30992","volume":"153B","author":"D Langbehn","year":"2010","unstructured":"Langbehn D, Hayden M, Paulsen J. CAG-repeat length and the age of onset in Huntington disease (HD): a review and validation study of statistical approaches. Am J Med Genet B Neuropsychiatr Genet. 2010;153B(2):397\u2013408.","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"issue":"2","key":"4396_CR5","doi-asserted-by":"publisher","first-page":"153","DOI":"10.3233\/JHD-210475","volume":"11","author":"JH Warner","year":"2022","unstructured":"Warner JH, Long JD, Mills JA, Langbehn DR, Ware J, Mohan A, Sampaio C. Standardizing the CAP Score in Huntington\u2019s Disease by Predicting Age-at-Onset. J Huntington\u2019s Disease. 2022;11(2):153\u201371.","journal-title":"J Huntington\u2019s Disease"},{"issue":"5","key":"4396_CR6","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1007\/s12311-022-01424-1","volume":"22","author":"LP Selvadurai","year":"2023","unstructured":"Selvadurai LP, Perlman SL, Wilmot GR, Subramony SH, Gomez CM, Ashizawa T, et al. The S-factor, a new measure of disease severity in spinocerebellar ataxia: findings and implications. Cerebellum. 2023;22(5):790\u2013809.","journal-title":"Cerebellum"},{"key":"4396_CR7","doi-asserted-by":"crossref","unstructured":"Petit E, Coarelli G, Morgan D, Cunha P, Hurmic H, Faber J et al. Predictive models for ataxia progression and conversion in spinocerebellar ataxia type 1 and 3. Brain. 2025.","DOI":"10.1093\/brain\/awaf408"},{"issue":"5","key":"4396_CR8","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1002\/mdc3.70010","volume":"12","author":"M Farag","year":"2025","unstructured":"Farag M, Knights H, Scahill RI, McColgan P, Estevez-Fraga C. Neuroimaging Techniques in Huntington\u2019s Disease: A Critical Review. Mov Disorders Clin Pract. 2025;12(5):561\u201376.","journal-title":"Mov Disorders Clin Pract"},{"issue":"1","key":"4396_CR9","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s12311-021-01285-0","volume":"21","author":"A Nigri","year":"2022","unstructured":"Nigri A, Sarro L, Mongelli A, Castaldo A, Porcu L, Pinardi C, et al. Spinocerebellar ataxia type 1: one-year longitudinal study to identify clinical and MRI measures of disease progression in patients and presymptomatic carriers. Cerebellum. 2022;21(1):133\u201344.","journal-title":"Cerebellum"},{"issue":"7","key":"4396_CR10","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1002\/mdc3.12808","volume":"6","author":"CA Ross","year":"2019","unstructured":"Ross CA, Reilmann R, Cardoso F, McCusker EA, Testa CM, Stout JC, et al. Movement disorder society task force viewpoint: Huntington\u2019s disease diagnostic categories. Mov disorders Clin Pract. 2019;6(7):541.","journal-title":"Mov disorders Clin Pract"},{"issue":"4","key":"4396_CR11","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1007\/s12311-025-01856-5","volume":"24","author":"T Klockgether","year":"2025","unstructured":"Klockgether T, Grobe-Einsler M, Faber J. Biomarkers in Spinocerebellar Ataxias. Cerebellum. 2025;24(4):104.","journal-title":"Cerebellum"},{"key":"4396_CR12","unstructured":"Caron NS, Wright GEB, Hayden MR. Huntington disease. GeneReviews\u00ae[Internet]. 2020."},{"issue":"6","key":"4396_CR13","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/ejhg.2017.10","volume":"25","author":"JN Kohler","year":"2017","unstructured":"Kohler JN, Turbitt E, Biesecker BB. Personal utility in genomic testing: a systematic literature review. Eur J Hum Genet. 2017;25(6):662\u20138.","journal-title":"Eur J Hum Genet"},{"issue":"12","key":"4396_CR14","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1001\/jama.2013.113","volume":"309","author":"WG Feero","year":"2013","unstructured":"Feero WG, Wicklund C, Veenstra DL. The Economics of Genomic Medicine: Insights From the IOM Roundtable on Translating Genomic-Based Research for Health. JAMA. 2013;309(12):1235\u20136.","journal-title":"JAMA"},{"key":"4396_CR15","unstructured":"CureQ. CureQ: Predict, Delay & Cure polyglutamine(Q) caused neurodegeneration 2022 [cited 22-10-2025]. Available from: https:\/\/cureq.nl\/cureq-en\/."},{"issue":"6","key":"4396_CR16","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/S1474-4422(20)30143-5","volume":"19","author":"RI Scahill","year":"2020","unstructured":"Scahill RI, Zeun P, Osborne-Crowley K, Johnson EB, Gregory S, Parker C, et al. Biological and clinical characteristics of gene carriers far from predicted onset in the Huntington\u2019s disease Young Adult Study (HD-YAS): a cross-sectional analysis. Lancet Neurol. 2020;19(6):502\u201312.","journal-title":"Lancet Neurol"},{"issue":"1","key":"4396_CR17","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1212\/WNL.0000000000001711","volume":"85","author":"RPPWM Maas","year":"2015","unstructured":"Maas RPPWM, van Gaalen J, van de Klockgether T. The preclinical stage of spinocerebellar ataxias. Neurology. 2015;85(1):96\u2013103.","journal-title":"Neurology"},{"issue":"1","key":"4396_CR18","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1111\/j.1467-8519.2005.00424.x","volume":"19","author":"P Borry","year":"2005","unstructured":"Borry P, Schotsmans P, Dierickx K. The birth of the empirical turn in bioethics. Bioethics. 2005;19(1):49\u201371.","journal-title":"Bioethics"},{"issue":"1","key":"4396_CR19","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12910-018-0246-9","volume":"19","author":"T Wangmo","year":"2018","unstructured":"Wangmo T, Hauri S, Gennet E, Anane-Sarpong E, Provoost V, Elger BS. An update on the empirical turn in bioethics: analysis of empirical research in nine bioethics journals. BMC Med Ethics. 2018;19(1):6.","journal-title":"BMC Med Ethics"},{"key":"4396_CR20","doi-asserted-by":"crossref","unstructured":"Rensink MJ, Schermer MHN, Tibben A, Bijlsma EK, de Bot ST, Kievit JA, Bolt LLE. Exploring mutation carriers\u2019 preferences regarding onset and progression of disease predictions for adult-onset genetic neurodegenerative diseases: a qualitative interview study. Hum Genet. 2025:1\u201313.","DOI":"10.1007\/s00439-025-02750-0"},{"key":"4396_CR21","doi-asserted-by":"crossref","unstructured":"Moglia C, Palumbo F, Botto R, Iazzolino B, Ticozzi N, Calvo A, et al. Prognostic communication in amyotrophic lateral sclerosis: findings from a Nationwide Italian survey. Neurol Sci. 2024:1\u20138.","DOI":"10.1007\/s10072-024-07702-6"},{"issue":"12","key":"4396_CR22","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.3390\/brainsci11121597","volume":"11","author":"RM van Eenennaam","year":"2021","unstructured":"van Eenennaam RM, Koppenol LS, Kruithof WJ, Kruitwagen-van Reenen ET, Pieters S, van Es MA, et al. Discussing personalized prognosis empowers patients with amyotrophic lateral sclerosis to regain control over their future: a qualitative study. Brain Sci. 2021;11(12):1597.","journal-title":"Brain Sci"},{"issue":"5","key":"4396_CR23","first-page":"4363","volume":"30","author":"RB Parikh","year":"2022","unstructured":"Parikh RB, Manz CR, Nelson MN, Evans CN, Regli SH, O\u2019Connor N, et al. Clinician perspectives on machine learning prognostic algorithms in the routine care of patients with cancer: a qualitative study. Support Care Cancer. 2022;30(5):4363\u201372.","journal-title":"Support Care Cancer"},{"issue":"6","key":"4396_CR24","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1111\/hex.12196","volume":"18","author":"SAM Hallen","year":"2015","unstructured":"Hallen SAM, Hootsmans NAM, Blaisdell L, Gutheil CM, Han PKJ. Physicians\u2019 perceptions of the value of prognostic models: the benefits and risks of prognostic confidence. Health Expect. 2015;18(6):2266\u201377.","journal-title":"Health Expect"},{"issue":"6","key":"4396_CR25","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1093\/intqhc\/mzm042","volume":"19","author":"A Tong","year":"2007","unstructured":"Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. Int J Qual Health Care. 2007;19(6):349\u201357.","journal-title":"Int J Qual Health Care"},{"key":"4396_CR26","unstructured":"Government of the Netherlands. Is euthanasia allowed? Ministry of Health, Welfare and Sport; [cited 10-30-2024]. Available from: https:\/\/www.government.nl\/topics\/euthanasia\/is-euthanasia-allowed."},{"issue":"9","key":"4396_CR27","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1111\/bioe.12375","volume":"31","author":"RHP Wouters","year":"2017","unstructured":"Wouters RHP, Cornelis C, Newson AJ, Bunnik EM, Bredenoord AL. Scanning the body, sequencing the genome: Dealing with unsolicited findings. Bioethics. 2017;31(9):648\u201356.","journal-title":"Bioethics"},{"key":"4396_CR28","unstructured":"Stemkens D, van der Bruggenwirth HT. Dutch national consensus-based guideline for the disclosure of incidental findings during clinical genetic diagnostic testing. 2020."},{"issue":"1","key":"4396_CR29","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/s41531-025-01112-x","volume":"11","author":"Y Li","year":"2025","unstructured":"Li Y, McDonald-Webb M, McLernon DJ, Counsell CE, Macleod AD. Systematic review of prognostic models in Parkinson\u2019s disease. npj Parkinson\u2019s Disease. 2025;11(1):266.","journal-title":"npj Parkinson\u2019s Disease"},{"issue":"9","key":"4396_CR30","doi-asserted-by":"publisher","first-page":"3361","DOI":"10.1007\/s00415-021-10508-7","volume":"268","author":"L Xu","year":"2021","unstructured":"Xu L, He B, Zhang Y, Chen L, Fan D, Zhan S, Wang S. Prognostic models for amyotrophic lateral sclerosis: a systematic review. J Neurol. 2021;268(9):3361\u201370.","journal-title":"J Neurol"},{"issue":"10","key":"4396_CR31","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1038\/ejhg.2016.36","volume":"24","author":"SS Baig","year":"2016","unstructured":"Baig SS, Strong M, Rosser E, Taverner NV, Glew R, Miedzybrodzka Z, et al. 22 Years of predictive testing for Huntington\u2019s disease: the experience of the UK Huntington\u2019s Prediction Consortium. Eur J Hum Genet. 2016;24(10):1396\u2013402.","journal-title":"Eur J Hum Genet"},{"issue":"9","key":"4396_CR32","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1212\/01.WNL.0000032255.75650.C2","volume":"59","author":"C Goizet","year":"2002","unstructured":"Goizet C, Lesca G, D\u00fcrr A. Presymptomatic testing in Huntington\u2019s disease and autosomal dominant cerebellar ataxias. Neurology. 2002;59(9):1330\u20136.","journal-title":"Neurology"},{"issue":"1","key":"4396_CR33","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1080\/17579961.2021.1898299","volume":"13","author":"B-J Koops","year":"2021","unstructured":"Koops B-J. The concept of function creep. Law Innov Technol. 2021;13(1):29\u201356.","journal-title":"Law Innov Technol"},{"issue":"1","key":"4396_CR34","doi-asserted-by":"publisher","first-page":"W1","DOI":"10.7326\/M14-0698","volume":"162","author":"KGM Moons","year":"2015","unstructured":"Moons KGM, Altman DG, Reitsma JB, Ioannidis JPA, Macaskill P, Steyerberg EW, et al. Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): explanation and elaboration. Ann Intern Med. 2015;162(1):W1\u201373.","journal-title":"Ann Intern Med"},{"key":"4396_CR35","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.jclinepi.2021.01.009","volume":"132","author":"M Van Smeden","year":"2021","unstructured":"Van Smeden M, Reitsma JB, Riley RD, Collins GS, Moons KGM. Clinical prediction models: diagnosis versus prognosis. J Clin Epidemiol. 2021;132:142\u20135.","journal-title":"J Clin Epidemiol"},{"issue":"2","key":"4396_CR36","first-page":"e200427","volume":"15","author":"CM Considine","year":"2025","unstructured":"Considine CM, Eddy CM, Frank SA, Kostyk SK, Oosterloo M, Killoran A, et al. Improving the clinical diagnostic criteria for genetically confirmed adult-onset Huntington disease: considering nonmotor presentations. Neurology: Clin Pract. 2025;15(2):e200427.","journal-title":"Neurology: Clin Pract"},{"issue":"19","key":"4396_CR37","doi-asserted-by":"publisher","first-page":"e2395","DOI":"10.1212\/WNL.0000000000011893","volume":"96","author":"B McAllister","year":"2021","unstructured":"McAllister B, Gusella JF, Landwehrmeyer GB, Lee J-M, MacDonald ME, Orth M, et al. Timing and impact of psychiatric, cognitive, and motor abnormalities in Huntington disease. Neurology. 2021;96(19):e2395\u2013406.","journal-title":"Neurology"},{"issue":"6","key":"4396_CR38","doi-asserted-by":"publisher","first-page":"67","DOI":"10.3390\/brainsci7060067","volume":"7","author":"RA Paoli","year":"2017","unstructured":"Paoli RA, Botturi A, Ciammola A, Silani V, Prunas C, Lucchiari C, et al. Neuropsychiatric burden in Huntington\u2019s disease. Brain Sci. 2017;7(6):67.","journal-title":"Brain Sci"},{"issue":"19","key":"4396_CR39","doi-asserted-by":"publisher","first-page":"e2045","DOI":"10.1212\/WNL.0000000000008906","volume":"94","author":"AM Glidden","year":"2020","unstructured":"Glidden AM, Luebbe EA, Elson MJ, Goldenthal SB, Snyder CW, Zizzi CE, et al. Patient-reported impact of symptoms in Huntington disease: PRISM-HD. Neurology. 2020;94(19):e2045\u201353.","journal-title":"Neurology"},{"issue":"3","key":"4396_CR40","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1002\/mdc3.13148","volume":"8","author":"M Oosterloo","year":"2021","unstructured":"Oosterloo M, de Greef BTA, Bijlsma EK, Durr A, Tabrizi SJ, Estevez-Fraga C, et al. Disease onset in Huntington\u2019s disease: when is the conversion? Mov Disorders Clin Pract. 2021;8(3):352\u201360.","journal-title":"Mov Disorders Clin Pract"},{"key":"4396_CR41","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.parkreldis.2021.08.014","volume":"91","author":"R van de Maas","year":"2021","unstructured":"van de Maas R. Exploring the clinical meaningfulness of the Scale for the Assessment and Rating of Ataxia: A comparison of patient and physician perspectives at the item level. Parkinsonism Relat Disord. 2021;91:37\u201341.","journal-title":"Parkinsonism Relat Disord"},{"key":"4396_CR42","doi-asserted-by":"crossref","unstructured":"Kon\u00ed\u010dkov\u00e1 D, Men\u0161\u00edkov\u00e1 K, Tu\u010dkov\u00e1 L, H\u00e9nykov\u00e1 E, Strnad M, Friedeck\u00fd D, et al. Biomarkers of neurodegenerative diseases: biology, taxonomy, clinical relevance, and current research status. Biomedicines. 2022;10(7).","DOI":"10.3390\/biomedicines10071760"},{"issue":"6","key":"4396_CR43","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1038\/s41591-021-01382-x","volume":"27","author":"O Hansson","year":"2021","unstructured":"Hansson O. Biomarkers for neurodegenerative diseases. Nat Med. 2021;27(6):954\u201363.","journal-title":"Nat Med"},{"issue":"11","key":"4396_CR44","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1002\/mds.26012","volume":"29","author":"CA Ross","year":"2014","unstructured":"Ross CA, Pantelyat A, Kogan J, Brandt J. Determinants of functional disability in Huntington\u2019s disease: role of cognitive and motor dysfunction. Mov Disord. 2014;29(11):1351\u20138.","journal-title":"Mov Disord"},{"issue":"1","key":"4396_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0277-9536(94)90294-1","volume":"38","author":"LM Verbrugge","year":"1994","unstructured":"Verbrugge LM, Jette AM. The disablement process. Soc Sci Med. 1994;38(1):1\u201314.","journal-title":"Soc Sci Med"},{"key":"4396_CR46","first-page":"167","volume-title":"The sick role. Key Concepts in Medical Sociology","author":"LF Monaghan","year":"2022","unstructured":"Monaghan LF, Bury M. The sick role. Key Concepts in Medical Sociology. Third London: SAGE Publications, Inc; 2022. pp. 167\u201373."},{"issue":"6","key":"4396_CR47","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1002\/jgc4.1245","volume":"29","author":"KH Tiller\u00e5s","year":"2020","unstructured":"Tiller\u00e5s KH, Kjoelaas SH, Dramstad E, von der Feragen KB. Psychological reactions to predictive genetic testing for Huntington\u2019s disease: A qualitative study. J Genet Couns. 2020;29(6):1093\u2013105.","journal-title":"J Genet Couns"},{"issue":"3","key":"4396_CR48","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1111\/j.1399-0004.2012.01900.x","volume":"83","author":"R MacLeod","year":"2013","unstructured":"MacLeod R, Tibben A, Frontali M, Jones A, Martinez-Descales A, Roos RA, et al. Recommendations for the predictive genetic test in Huntington\u2019s disease. Clin Genet. 2013;83(3):221\u201331.","journal-title":"Clin Genet"},{"issue":"1","key":"4396_CR49","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1186\/s12883-020-02004-8","volume":"20","author":"RM van Eenennaam","year":"2020","unstructured":"van Eenennaam RM, Kruithof WJ, van Es MA, Kruitwagen-van Reenen ET, Westeneng HJ, Visser-Meily JMA, et al. Discussing personalized prognosis in amyotrophic lateral sclerosis: development of a communication guide. BMC Neurol. 2020;20(1):446.","journal-title":"BMC Neurol"},{"issue":"1","key":"4396_CR50","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/s10897-010-9329-6","volume":"20","author":"A Hagberg","year":"2011","unstructured":"Hagberg A, Bui TH, Winnberg E. More appreciation of life or regretting the test? Experiences of living as a mutation carrier of Huntington\u2019s disease. J Genet Couns. 2011;20(1):70\u20139.","journal-title":"J Genet Couns"},{"issue":"2","key":"4396_CR51","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1037\/0278-6133.23.2.189","volume":"23","author":"R Timman","year":"2004","unstructured":"Timman R, Roos R, Maat-Kievit A, Tibben A. Adverse effects of predictive testing for Huntington disease underestimated: long-term effects 7\u201310 years after the test. Health Psychol. 2004;23(2):189.","journal-title":"Health Psychol"},{"key":"4396_CR52","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s10897-014-9755-y","volume":"24","author":"S Crozier","year":"2015","unstructured":"Crozier S, Robertson N, Dale M. The psychological impact of predictive genetic testing for Huntington\u2032 s disease: a systematic review of the literature. J Genet Couns. 2015;24:29\u201339.","journal-title":"J Genet Couns"},{"key":"4396_CR53","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.pneurobio.2013.08.003","volume":"110","author":"JS Paulsen","year":"2013","unstructured":"Paulsen JS, Nance M, Kim J-I, Carlozzi NE, Panegyres PK, Erwin C, et al. A review of quality of life after predictive testing for and earlier identification of neurodegenerative diseases. Prog Neurobiol. 2013;110:2\u201328.","journal-title":"Prog Neurobiol"},{"issue":"1","key":"4396_CR54","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s13195-016-0212-z","volume":"8","author":"SA Bemelmans","year":"2016","unstructured":"Bemelmans SA, Tromp K, Bunnik EM, Milne RJ, Badger S, Brayne C, et al. Psychological, behavioral and social effects of disclosing Alzheimer\u2019s disease biomarkers to research participants: a systematic review. Alzheimers Res Ther. 2016;8(1):46.","journal-title":"Alzheimers Res Ther"},{"key":"4396_CR55","doi-asserted-by":"crossref","unstructured":"Ormond KE, Laurino MY, Barlow-Stewart K, Wessels TM, Macaulay S, Austin J, Middleton A, editors. Genetic counseling globally: Where are we now? American Journal of Medical Genetics Part C: Seminars in Medical Genetics. Wiley Online Library; 2018.","DOI":"10.1002\/ajmg.c.31607"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-026-04396-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04396-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04396-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T14:04:18Z","timestamp":1780063458000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13023-026-04396-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,13]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4396"],"URL":"https:\/\/doi.org\/10.1186\/s13023-026-04396-1","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,13]]},"assertion":[{"value":"4 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was granted a waiver on March 4th 2024 by the institutional research review board of the Erasmus MC, confirming that this study is exempt from the Dutch Medical Research Involving Human Subjects Act (WMO) (MEC-2022-0827). All participants provided (digitally) signed informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and informed consent"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"208"}}